<DOC>
	<DOCNO>NCT00252954</DOCNO>
	<brief_summary>Purpose : To evaluate efficacy safety levetiracetam chronic neuropathic pain spinal cord injury , examine effect spasm evoke pain .</brief_summary>
	<brief_title>Levetiracetam Chronic Neuropathic Pain Following Spinal Cord Injury</brief_title>
	<detailed_description>Study design : Randomized double-blind cross-over study levetiracetam ( Keppra ) correspond placebo 1 week baseline period follow 2 x 5 week treatment period separate 1 week wash-out period . Methodology : Levetiracetam correspond placebo gradually increase two week 500 mg x 2 daily 1500 mg x 2 daily ( 1000 mg x 2 daily allow 1500 mg x 2 tolerate ) , keep dose three week . The study monitor GCP unit Aarhus Copenhagen University .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Spinal Injuries</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>1. age 18 2. neuropathic pain ( last least 3 month ) spinal cord injury pain intensity least 4 010 point numeric rating scale 1. pregnancy lactation 2. allergy levetiracetam 3. alcohol substance abuse , mental disease , epilepsy , depression psychiatric disorder , severe liver disease , decrease kidney function , know concomitant cerebral damage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Spinal cord injury</keyword>
	<keyword>Neuropathic pain</keyword>
	<keyword>Spasms</keyword>
</DOC>